Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 10.0 NORMAL Primary: Spectral Shift

$60B+ market cap (Copenhagen-listed), Novo Nordisk manufactures insulin, GLP-1 agonists, and hormone therapies. Launched high-dose Wegovy formulation in latest quarter as generic weight-loss drugs erode market share in India; Eli Lilly pressure intensifying in obesity treatment segment.

High-dose Wegovy (semaglutide) product line expansion; competitive positioning against Eli Lilly in weight-loss drug market amid generic competition in emerging markets
-0.22
PSI Score
10.0
Momentum
1%
Confidence
10
Connections
Connected Entities
FDA China India United States Eli Lilly Canada OpenAI Bloomberg Netflix Sanofi
Watch This Entity
PSI Intelligence
30-Day Trend
2026-03-20 2026-04-17 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.000
Narrative Drift
0.000
Spectral Shift
831.349
Sentiment-Momentum Divergence
0.000
Source Concentration
0.642
Network Analysis
10 Degree Centrality
Centrality History
2026-03-20 2026-04-17 10 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 12 NEW
China 9 NEW
India 8 NEW
United States 8 NEW
Eli Lilly 7 NEW
Canada 6 NEW
OpenAI 4 NEW
Bloomberg 2 NEW
Netflix 2 NEW
Sanofi 1 NEW
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-04-17 ← Intelligence Network